A Phase 2, Open-Label, Multi-Center Dose Escalation Study of the Safety, Pharmacodynamics, and Pharmacokinetics of Subcutaneously Administered Peginesatide in Anemic Cancer Patients Receiving Chemotherapy
Latest Information Update: 03 Oct 2021
At a glance
- Drugs Peginesatide (Primary)
- Indications Chemotherapy-induced anaemia
- Focus Pharmacodynamics
- Sponsors Affymax
- 23 May 2014 New trial record